Conavi Medical Income Statement

Financials in millions CAD. Fiscal year is October - September.

Millions CAD. Fiscal year is Oct - Sep.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022
Revenue	9.12	2.16	2.36	2.7
Revenue Growth (YoY)	322.12%	-8.59%	-12.44%	-
Cost of Revenue	1.5	2.11	0.96	1.01
Gross Profit	7.63	0.05	1.4	1.69
Selling, General & Admin	6.15	7.07	6.3	5.22
Research & Development	15.27	17.94	15.2	5.58
Other Operating Expenses	0.25	0.29	0.23	0.09
Operating Expenses	22.48	26.29	23.03	11.98
Operating Income	-14.85	-26.23	-21.63	-10.28
Interest Expense	-11.69	-8.02	-5.64	-4.09
Interest & Investment Income	0.14	0.25	0.28	0.05
Currency Exchange Gain (Loss)	-0.07	-0.55	0.76	2.47
Other Non Operating Income (Expenses)	0.1	-	-	-
EBT Excluding Unusual Items	-26.37	-34.55	-26.22	-11.87
Gain (Loss) on Sale of Investments	-	-	0.13	-
Other Unusual Items	5.85	-9.07	-	-
Pretax Income	-20.52	-43.62	-26.09	-11.87
Net Income	-20.52	-43.62	-26.09	-11.87
Net Income to Common	-20.52	-43.62	-26.09	-11.87
Shares Outstanding (Basic)	58	6	6	6
Shares Outstanding (Diluted)	58	6	6	6
Shares Change (YoY)	833.52%	0.08%	0.00%	-
EPS (Basic)	-0.36	-7.08	-4.24	-1.93
EPS (Diluted)	-0.36	-7.08	-4.24	-1.93
Free Cash Flow	-25.17	-20.72	-20.66	-9.78
Free Cash Flow Per Share	-0.44	-3.36	-3.36	-1.59
Gross Margin	83.61%	2.45%	59.22%	62.67%
Operating Margin	-162.81%	-1213.93%	-914.76%	-380.89%
Profit Margin	-224.91%	-2018.28%	-1103.51%	-439.52%
Free Cash Flow Margin	-275.96%	-958.95%	-874.07%	-362.22%
EBITDA	-14.37	-25.6	-20.71	-9.61
EBITDA Margin	-157.49%	-	-	-
D&A For EBITDA	0.49	0.64	0.92	0.67
EBIT	-14.85	-26.23	-21.63	-10.28
EBIT Margin	-162.81%	-	-	-
Revenue as Reported	9.12	2.16	2.36	2.7

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.